Wed., August 20, 2008 | | Archives | Advertising | Your Account | CHI Conferences |  Subscribe |
Sales Contacts
For advertising information contact: 

Alan El Faye
VP, Advertising Sales - CA, Western US, Midwest, South Eastern US, Europe, Canada, Pacific Rim

Kay O. Christopher
Regional Sales Manager, Advertising Sales -New England, North Eastern US

Tom Loughran
Regional Sales Manager, Advertising Sales -Midwest, South Eastern US, Europe

Contact the Editor
PharmaWeek welcomes your feedback. Please contact Catherine Varmazis or Allison Proffitt for editorial inquiries. 

Link to Us! 
You are welcome to link to articles on our website. Contact Catherine Varmazis for details.

e-Prints & Reprints 
To post a full article from PharmaWeek or Bio-IT World on your website (not just a link), or for paper reprints, please contact:
Becky Mullaney
The YGS Group
717-399-1900 ext.125

Dear Colleague,
Welcome to this week's eNewsletter covering breaking R&D news, business insights, and opinion piece: Expanding Cancer Targets, by Irena Melnikova.


A Dark Cloud Over Amylin [Aug. 19, 2008] Worries that Byetta might harm the pancreas have dogged the drug's makers, biotech Amylin Pharmaceuticals and drug giant Eli Lilly, for more than two years. On Monday, the FDA sent out an alert saying that it was looking into six new cases of pancreatitis, that two patients had died, and that the agency was working with Amylin "to add stronger and more prominent warnings in the product label about the risk of acute hemorrhagic or necrotizing pancreatitis." More

Alnylam Inks Deal with Max Planck
Boston Business Journal [Aug. 11, 2008] Alnylam Pharmaceuticals Inc. has signed a collaboration deal with a German research institute to find ways to make sure new RNAi treatments reach their targets. More

Scientists Turn Proteins into Stem Cells
Brisbane Times [Aug. 11, 2008] Queensland scientists have successfully turned synthetic material into an embryonic stem cell, in a research breakthrough that may one day quell the debate over stem cell therapies. More

Researchers Find Genetic Link to Colon Cancer
Yahoo!News [Aug. 14, 2008] U.S. researchers have discovered a genetic trait that shows the strongest link yet to colorectal cancer, the number-two cancer killer in the United States, according to a study published Thursday. More

Gene Hunt Hints at Cause of Bipolar Disorder
New York Times [Aug. 15, 2008] A gene hunt among more than 4,000 British, Irish and American patients suffering from bipolar disorder has turned up two genes that put new emphasis on a possible cause of the disease. More


Faith Slipping in Meaningful Pfizer Deal
Reuters [Aug. 11, 2008] AFaith Slipping in Meaningful Pfizer Deal
As proposed buyouts sweep through the drug sector, Pfizer's failure in recent years to buy another big rival has surprised many investors, some of whom say its too late for a big acquisition to rescue the No. 1 drugmaker. More

Genentech Rejects Takeover Bid from Roche
New York Times [Aug. 14, 2008] Roche  is expected to increase its offer for Genentech now that an initial $43.7 billion bid has been rejected, analysts said Wednesday. Genentech said that a special committee of directors had found that Roche’s offer of $89 a share “substantially undervalues the company.” More

Biotech Campaigns for Easier Access to Generic Drug Market
Washington Post [Aug. 12, 2008] The chief executive of Insmed -- a small Richmond biotech whose goal is to be the first U.S. company to develop a portfolio of biotech generics, or "biosimilars" --  has been giving Congress a lesson in biotechnology.  His company's success rides on Congress overhauling the laws to permit competition that would result in lower biologic drug prices. More

First U.S. Drug for Huntington's Wins FDA Approval
Associated Press [Aug. 15, 2008] Federal regulators on Friday cleared the first treatment approved in the United States for Huntington's disease. The medication, called Xenazine, will not cure the condition_and it has some potentially serious side effects, such as raising the risk of suicidal behavior. However, it does provide relief for a major disabling symptom of Huntington's. More

Cytos Shares Surge on Pfizer Vaccine Deal
Reuters [Aug. 15, 2008] Swiss biotech Cytos has entered a vaccine deal with Pfizer in which it will receive an upfront payment of 150 million Swiss francs ($138 million) and potential further milestones, Cytos said on Friday. In return, the agreement will allow the U.S. drug maker to acquire world-wide exclusive rights to commercialize certain vaccines, based on Cytos Biotechnology's Immunodrug technology. More





Isilon Systems ~ Senior Marketing Communications Manager
Isilon Systems is the worldwide leader in clustered storage systems and software for digital content and unstructured data. We seek an experienced marketing communications professional/writer expert in creating and delivering effective and persuasive business communications. The ideal candidate can think at the strategic and conceptual level and act, simultaneously, as a highly-effective and productive individual contributor. The position is based in Seattle, WA. For additional information
 click here

Lilly Singapore Center for Drug Discovery (LSCDD) - Associate Director of Informatics,
Lead and mentor a strong team for the Bioinformatics group at the Integrative Computational Sciences (ICS) department at LSCDD towards the development of novel algorithms, data analysis methods and software tools for drug discovery. Work closely with the Software Engineering group at ICS, and collaborate with the Discovery IT organization in Europe and USA. For additional information, or to apply visit:

Lilly Singapore Center for Drug Discovery (LSCDD)- Senior Bioinformatics Scientist,
Contribute to the development of novel algorithms, data analysis methods and software tools for drug discovery as part of the Integrative Computational Sciences (ICS) department at LSCDD.  Work closely with informatics and software engineering peers at ICS, and collaborate with the Discovery IT organization in Europe and USA. The successful candidate will offer hands-on insight and expertise in tailored therapeutic informatics and statistical analyses at the post-genomic era. For additional information, or to apply visit:

Lilly Singapore Center for Drug Discovery (LSCDD) - Manager, Software Engineering (Integrative Computational Sciences)
Join the Integrative Computational Sciences (ICS) department at Lilly Singapore Centre for Drug Discovery (LSCDD),as Manager Software Engineering.  Lead the development of integrated applications to process and visualize data from cutting edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. Masters in Computer Science/Engineering or related discipline, 10+ years post graduation experience , 2 years management experience needed. For a complete job description and requirements or to apply visit:

Lilly Singapore Center for Drug Discovery(LSCDD) -Senior Software Engineer,
Join a strong team of software engineers in our Integrative Computational Sciences (ICS) at LSCDD. Collaborate with, and help develop integrated applications to process and visualize data from cutting-edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. The Software Engineering team provides computational tools and tailored software solutions that enable the global effort of Tailored Therapeutics; ‘The Right Drug, at The Right Dose for The Right Patient at The Right Time'. For additional information, or to apply visit:

Linguamatics, Applications Specialist, Life Sciences Text Mining Software - Northeast U.S.*
Linguamatics, a leader in semantic search and text mining for the
pharma/biotech industry, is looking for an experienced life science
focused applications specialist to demonstrate the value of our products and help drive the growth of our North American business.  For further information visit:

Memorial Sloan-Kettering Cancer Center - Linux Systems Administrator
MSKCC Bioinformatics Core in Manhattan seeks Linux Systems Administrator. Install, configure, update, monitor and troubleshoot HPC cluster, email and web servers. Bachelor's degree and 3 years experience with HPC, network security, Postfix, Apache, Tomcat, Grid Engine, Solaris. Email #015429. EOE/AA

More Life Science Jobs ~ Add a Job Listing




ELNs: Advanced Laboratory Solutions-September 15 - 17 2008 • Crowne Plaza, Brussels, Belgium 

Discovery Knowledge & Informatics - September 15 - 17, 2008 • Crowne Plaza, Brussels, Belgium 

Multiplexed Genomics Tools: Targeting the Missing Links
Between Health and Disease - September 21-23, 2008 • Providence, RI

Next-Generation Sequencing Data Analysis -September 22-23, 2008 • Providence, RI

Harvard Biomed HPC Leadership Summit 2008, October 5~7, 2008, Boston, MA USA

DIA 2nd Annual Clinical Forum:
 Data Driven Drug Development Decisions - October 20-23, 2008 | Ljubljana, Slovenia

Barnett Educational Services, 
2008 Schedule

To have your event featured here, contact Lynn Cloonan for more information.

 Email to a Friend 


Expanding Cancer Targets
By Irena Melnikova

The World Health Organization estimates that by 2020, there will be 16 million new cancer cases every year, and there is a continual need for novel therapies that will command premium pricing. In addition, as new medicines prolong life, some current short-term agents could see extended usage, thereby generating additional sales. These forces are driving the expansion of the global oncology market.

Despite the wealth of potential targets, current drugs address only a handful of the best-characterized oncogenesis pathways, but the number of targets is growing exponentially. While not all of these targets will work, several have the potential to improve efficacy for many tumor types, and contribute significantly to the oncology market over the next five years. 
Read More


Life Science Webcasts from Bio-IT World and Cambridge Healthtech Media Group

Life Science Webcasts

Bio-IT World Expo
Video Highlights


Drug Discovery, Development and Commercialization: Evolving Challenges and Opportunities
Joshua Boger, PhD, president and CEO, Vertex Pharmaceuticals Inc., delivers his keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 2008.
View the Webcast Now.

Personalized Genetics: Advancements and Driving Change
Linda Avey, co-founder of 23andMe, delivers her keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.
View the Webcast Now.

The Future of Personal Genomics
A distinguished panel of personal genomics experts discuss the future of personal genomics at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.  They include Dietrich Stephan (co-founder, Navigenics); George Church (Harvard Medical School);
Jeff Drazen (editor-in-chief, New England Journal Medicine); Fred Ledley (Bentley College); John Halamka (CIO, Harvard Medical School); and Linda Avey (23andMe). Bio-IT World Editor-in-Chief Kevin Davies moderates the discussion.
View the Webcast Now

Insight Pharma Reports

Cancer Biomarkers: Adoption Is Driving Growth 

In-depth analysis of factors driving cancer biomarker growth and commercialization, product opportunities, business models, projected growth areas, survey results.
More Information 

Custom Market Research Services
Our experienced research team will work with you to fully understand your needs in order to create and conduct a custom market research program that meets your objectives.
Learn More

Featured Content

Enabling Translational
 Research Informatics
Learn about the challenges facing life sciences research labs to manage their translational research data:
The trends for organizations to adopt informatics solutions for translational research.
The unique requirements with managing complex data and workflow. What labs should consider when reviewing informatics solutions for translational research.
Which life sciences research organizations are successfully adopting an informatics solution.Download Now

Spain’s Emerging Biotech Revolution
The biotechnology sector is growing 10 percent faster in Spain than it is in the U.S. Driven by a culture, government and private sector that are open-minded and optimistic, Spain-based companies are emerging as leaders in this dynamic field. Discover how your business can capitalize on creative solutions from Spain-based enterprises. Download Now

Will Healthcare IT Trends Standardize?
A new wave of activities are driving transformation within the healthcare market. One solution is found in a guide to PDF Healthcare Best Practices. This “Best Practices Guide” describes Portable Document Format (PDF) attributes and use to facilitate the capture, exchange, preservation and protection of healthcare information. This webinar will focus on trends in today’s healthcare market, the challenges in overcoming these issues, and finally how to use best practices to improve patient care, enhance productivity and eliminate paperwork. It’s hosted by Adobe and moderated by Digital Healthcare & Productivity Executive Editor, John Russell. Click here...


Automate Method SOPs for Greater Efficiency and Fewer Errors with Waters® NuGenesis® Intelligent Procedure Manager
The Waters® NuGenesis® SDMS Intelligent Procedure Manager is a workflow software package designed to guide the laboratory analyst through a routine, comprehensive method standard operating procedure (SOP) and integrate results with a chromatography data system. The Intelligent Procedure Manager addresses the predominately manual activities required to perform an analytical method or test, reducing cycle times up to 50-75% as compared to a traditional paper trail with fewer opportunities for human error.  From late-stage development to final product quality control and lot release, Intelligent Procedure Manager can be applied to any lab environment where rigorous adherence to approved test methods and SOPs must be followed, including compliance requirements for cGMP operations.Download Now

To have your white paper featured here, contact Lynn Cloonan for more information.

                                Healthtech InstitutePublished by Cambridge Healthtech Institute (CHI). Copyright © 2008, all rights reserved. No material may be reproduced electronically or in print without written permission from CHI, 250 First Ave., Needham, MA 02494-2814. For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA; 17601 717-399-1900 ext.125, or email: